Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists test new Drug's hidden interactions

NCT ID NCT06813924

Summary

This study tested whether a new drug being developed for sickle cell disease and thalassemia, called etavopivat, changes how the body processes five other common medications. Healthy adult volunteers took etavopivat along with single doses of digoxin, rosuvastatin, midazolam, pitavastatin, and metformin. The goal was to measure drug levels in the blood to see if etavopivat made these other drugs stronger, weaker, or last longer in the body.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS SICKLE CELL DISEASE, THALASSEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • ICON-Salt Lake City

    Salt Lake City, Utah, 84124, United States

Conditions

Explore the condition pages connected to this study.